LTRNLantern Pharma Inc
LTRN
Lantern Pharma Inc1,518
Mkt Cap
$23.76MVolume
259,274.0052W High
$5.7452W Low
$1.11PE Ratio
-1.35LTRN Fundamentals
Price
$2.12Prev Close
$2.05Open
$2.0750D MA
$2.30Beta
1.87Avg. Volume
383,200.37EPS (Annual)
-$1.57P/B
3.65Rev/Employee
$0.00$22.98
Lantern Pharmas predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR AI platform, today announced the expansion of predictBBB.ai into a...
Business Wire·4d ago
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic...
Business Wire·9d ago
Emerging Data for Lantern Pharmas Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure With No Added Toxicity
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to...
Business Wire·13d ago
Lantern Pharma Launches withZeta.ai the Worlds First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
Lantern Pharma Inc. (Nasdaq: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai the worlds first and most comprehensive...
Business Wire·19d ago
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai the World's First Multi-Agentic Co-Scientist for Rare Cancers 8:30 AM Eastern, April 9, 2026
Lantern Pharma Inc. (Nasdaq: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on...
Business Wire·1mo ago
AI and Biotech Enter a Stock Picker’s Market
The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT
24-7 Market News·1mo ago
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost...
Business Wire·1mo ago
Why Is Lantern Pharma Stock Soaring Monday?
Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding CEO Panna Sharma's departure.read more...
Benzinga·1mo ago
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AIdriven, clinicalstage oncology company leveraging its proprietary RADR platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on...
Business Wire·1mo ago
<
1
2
...
>